Toxic glycoproteins isolated from European mistletoe, Viscum album L., Viscaceae, and related species. Type II ribosome inactivating proteins, similar to ricin, q.v.; inhibit protein synthesis and induce apoptosis. Comprised of 2 polypeptide chains, the cytotoxic A chain is linked to the carbohydrate-binding B chain via a disulfide bridge. Three isoforms have been identified that differ in carbohydrate binding specificity. Isoln of ML-I: P. Ziska et al., Experientia 34, 123 (1978); P. Luther et al., Int. J. Biochem. 11, 429 (1980) DOI PubMed; S. Olsnes et al., J. Biol. Chem. 257, 13263 (1982) PubMed; of I, II and III: H. Franz et al., Biochem. J. 195, 481 (1981) PubMed. Characterization and bioactivities: eidem, Oncology 43, Suppl. 1, 22 (1986) PubMed. Amino acid sequence of ML-I A chain: M. H. Soler et al., FEBS Lett. 399, 153 (1996) DOI PubMed; of B chain: idem et al., Biochem. Biophys. Res. Commun. 246, 596 (1998) DOI PubMed. Crystal structure of ML-I: R. Krauspenhaar et al., ibid. 257, 418 (1999) DOI PubMed. Structure of ML-III A chain: R. Wacker et al., J. Pept. Sci. 10, 138 (2004) DOI PubMed; of B chain: idem et al., ibid. 11, 289 (2005) DOI PubMed. Review of cytotoxic and immunostimulant activities: T. Hajtó et al., Evid. Based Complement. Altern. Med. 2, 59-67 (2005) DOI PubMed.
Nonglycosylated ML-I produced by recombinant technology in E. coli. mol wt 57 kDa. Cloning and characterization: J. Eck et al., Eur. J. Biochem. 264, 775 (1999) DOI PubMed; idem et al., ibid. 265, 788 (1999) DOI PubMed. Determn in plasma by immuno-polymerase chain reaction (IPCR) assay: M. Adler et al., J. Pharm. Biomed. Anal. 39, 972 (2005) DOI PubMed. Clinical pharmacology in patients with solid tumors: P. Schffski et al., Eur. J. Cancer 41, 1431 (2005) DOI PubMed.